Senhwa Biosciences Inc AI Stock Analysis
Senhwa Biosciences Inc (6492) AI Stock Analysis
Senhwa Biosciences Inc
(TPEx:6492)
The overall score is the minimum 37, reflecting a convergence of severe weaknesses. The company is a pre-revenue biotech with massive, cash-consuming losses and no near-term path to profitability, which is the most significant factor. This is compounded by a bearish technical breakdown with the stock in a deep downtrend and oversold conditions. The negative P/E ratio confirms the lack of earnings support. The only positive, a solid balance sheet, is overshadowed by the rapid equity erosion funding ongoing operations.
Senhwa Biosciences Inc (6492) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.41B
- Dividend Yield
- ―
- Average Volume (3M)
- 232.03K
- Price to Earnings (P/E)
- -9.1
- Beta (1Y)
- 0.53
- Revenue Growth
- 5.00%
- EPS Growth
- -6.49%
- Country
- TW
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Senhwa Biosciences Inc Business Overview & Revenue Model
Company Description
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its...
Senhwa Biosciences Inc Financial Statement Overview
Summary
Financial performance is critically weak. The company is pre-revenue with minimal sales (NT$1.07M) and deep net losses exceeding NT$264M. Cash flow is severely negative (NT$248.5M operating burn), mirroring losses. The only mitigating factor is a strong, debt-light balance sheet with NT$761M in equity, providing a cash runway. However, the rapid cash consumption and lack of profitability drive the lowest possible score.
Income Statement
8Very NegativeBalance Sheet
65PositiveCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.05M | 1.07M | 1.00M | 1.00M | 1.00M | 550.00K |
| Gross Profit | 443.00K | 520.00K | 477.00K | 552.00K | -6.61M | -5.91M |
| EBITDA | -302.91M | -266.15M | -279.71M | -283.79M | -340.60M | -321.59M |
| Net Income | -296.60M | -264.77M | -293.75M | -296.31M | -349.63M | -329.26M |
Balance Sheet | ||||||
| Total Assets | 679.25M | 819.26M | 1.07B | 1.36B | 1.65B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 636.92M | 771.78M | 1.03B | 1.32B | 1.62B | 2.03B |
| Total Debt | 17.92M | 22.12M | 14.99M | 9.60M | 16.16M | 15.38M |
| Total Liabilities | 62.61M | 58.30M | 38.92M | 46.17M | 40.93M | 92.44M |
| Stockholders Equity | 616.64M | 760.96M | 1.03B | 1.32B | 1.61B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | -257.22M | -248.74M | -296.17M | -291.13M | -400.34M | -300.45M |
| Operating Cash Flow | -256.71M | -248.46M | -294.22M | -286.35M | -399.97M | -300.05M |
| Investing Cash Flow | 4.63M | 5.82M | 6.71M | -5.26M | -590.00K | 149.00K |
| Financing Cash Flow | -9.60M | -9.34M | -8.72M | -8.83M | -19.55M | -34.24M |
Senhwa Biosciences Inc Peers Comparison
Overall Rating
TW:178664Neutral- TW:649237Underperform
TW:687537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1786 | 64Neutral | TWD 3.89B | 26.80 | ― | 3.67% | -2.25% | -15.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6492 | 37Underperform | TWD 3.44B | -9.10 | ― | ― | 5.00% | -6.49% |
| TW:6875 | 37Underperform | TWD 3.24B | -9.23 | ― | ― | -69.26% | -24.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6492 | Senhwa Biosciences Inc | 29.85 | -11.77 | -28.28% | |
| TW:1786 | SciVision Biotech Inc. | 49.10 | -22.96 | -31.86% | |
| TW:6838 | Formosa Pharmaceuticals, Inc. | 20.05 | -7.60 | -27.49% | |
| TW:6875 | Pharmosa Biopharm Inc. | 24.70 | -24.80 | -50.10% | |
| TW:6885 | BRIM Biotechnology, Inc. | 28.55 | -1.00 | -3.38% | |
| TW:7427 | Great Novel Therapeutics Biotech & Medicals Corp. | 58.60 | 18.23 | 45.16% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026